VIVUS (VVUS) Sets New 52-Week Low at $2.53

Shares of VIVUS, Inc. (NASDAQ:VVUS) reached a new 52-week low during trading on Thursday . The company traded as low as $2.53 and last traded at $2.59, with a volume of 2472 shares changing hands. The stock had previously closed at $2.60.

VVUS has been the topic of a number of analyst reports. Zacks Investment Research reaffirmed a “strong-buy” rating and set a $4.75 price objective on shares of VIVUS in a research note on Saturday, November 17th. ValuEngine raised VIVUS from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 12th.

The company has a market cap of $27.64 million, a P/E ratio of -0.88 and a beta of 0.70.

VIVUS (NASDAQ:VVUS) last posted its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.87) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.24. The company had revenue of $18.09 million for the quarter. On average, equities research analysts expect that VIVUS, Inc. will post -3.59 EPS for the current year.

In related news, CFO Mark K. Oki acquired 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 6th. The shares were acquired at an average price of $4.07 per share, with a total value of $40,700.00. Following the completion of the purchase, the chief financial officer now directly owns 10,000 shares in the company, valued at $40,700. The purchase was disclosed in a document filed with the SEC, which is available through this link. 8.60% of the stock is owned by company insiders.

An institutional investor recently bought a new position in VIVUS stock. Worth Venture Partners LLC purchased a new position in VIVUS, Inc. (NASDAQ:VVUS) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 30,000 shares of the biopharmaceutical company’s stock, valued at approximately $132,000. Worth Venture Partners LLC owned about 0.28% of VIVUS at the end of the most recent quarter. 17.02% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “VIVUS (VVUS) Sets New 52-Week Low at $2.53” was reported by WKRB News and is the property of of WKRB News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at

VIVUS Company Profile (NASDAQ:VVUS)

VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

Read More: What is a Leveraged Buyout (LBO)?

Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with's FREE daily email newsletter.

Leave a Reply